-+ 0.00%
-+ 0.00%
-+ 0.00%

Allurion Technologies Presents Study On Increasing Muscle Mass And Decreasing Fat Mass In Patients Treated With Allurion Program At SOFFCO.MM

Benzinga·05/27/2025 20:14:33
Listen to the news

In 1,962 patients treated in France with the Allurion Program, muscle mass as a percentage of total body weight increased, on average, by 6.6% and fat mass decreased, on average, by 11%

Company announces that shipments to France have resumed, and patient treatments are expected to resume next month

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l'Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025.

The study, entitled "The Swallowable Gastric Balloon Program with AI Powered Health Coach Leads to Metabolically Healthy Weight Loss in French Patients," assessed 1,962 patients in France treated with the Allurion Program. After just four months, the average reduction in total body weight was 12.2%. Lean body mass and muscle mass as a percentage of total body weight increased, on average, by 6.0% and 6.6%, respectively. Fat mass and visceral fat index decreased, on average, by 11% and 12.2%, respectively.